Literature DB >> 3041491

Pathogenesis of systemic lupus erythematosus.

A D Steinberg1, D M Klinman.   

Abstract

SLE is a syndrome characterized by diverse clinical signs and symptoms, including rash, serositis, nephritis, central nervous system disease, thrombocytopenia, and leukopenia. These and other manifestations are present in patients with immune abnormalities indicative of B cell hyperactivity: hypergammaglobulinemia, increased amounts of antibodies reactive with self-determinants (characteristically including nuclear antigens), and increased numbers of circulating antibody-producing cells. It is this immune hyperactivity, inclusive of anti-self responses, which groups the patients with diverse clinical manifestations into a single syndrome called lupus.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3041491

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  14 in total

1.  Urine free light chains in SLE: clonal markers of B-cell activity and potential link to in vivo secreted Ig.

Authors:  J E Hopper; J Golbus; C Meyer; G A Ferrer
Journal:  J Clin Immunol       Date:  2000-03       Impact factor: 8.317

2.  Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus.

Authors:  C O Jacob; Z Fronek; G D Lewis; M Koo; J A Hansen; H O McDevitt
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

3.  Anti-ribosomal antibodies bind the Sm proteins D and B/B'.

Authors:  L Caponi; S Bombardieri; P Migliorini
Journal:  Clin Exp Immunol       Date:  1998-04       Impact factor: 4.330

4.  Enhanced oxidative status but not corresponding elevated antioxidative status by anticardiolipin antibody and disease activity in patients with systemic lupus erythematosus.

Authors:  Wen-Nan Huang; Tim K Tso; Hui-Yu Huang
Journal:  Rheumatol Int       Date:  2007-03       Impact factor: 2.631

5.  Molecular basis of an autoantibody-associated restriction fragment length polymorphism that confers susceptibility to autoimmune diseases.

Authors:  T Olee; P M Yang; K A Siminovitch; N J Olsen; J Hillson; J Wu; F Kozin; D A Carson; P P Chen
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

Review 6.  Current concepts of neuropsychiatric systemic lupus erythematosus (NP-SLE).

Authors:  R A Asherson; S D Denburg; J A Denburg; R M Carbotte; N Futrell
Journal:  Postgrad Med J       Date:  1993-08       Impact factor: 2.401

7.  Serum adenosine deaminase activity in patients with systemic lupus erythematosus: a study based on ADA1 and ADA2 isoenzymes pattern.

Authors:  Reza Saghiri; Niloufar Ghashghai; Shafieh Movaseghi; Pegah Poursharifi; Shohreh Jalilfar; Manijeh Ahmadi Bidhendi; Leila Ghazizadeh; Mina Ebrahimi-Rad
Journal:  Rheumatol Int       Date:  2011-02-25       Impact factor: 2.631

8.  Systemic lupus erythematosus--changing disease patterns in the disease course. Dutch experience with 110 patients studied prospectively.

Authors:  A J Swaak; W Bronsveld; E J Nieuwenhuys; J C Nossent; R J Smeenk
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

9.  A positive correlation between homocysteine and brachial-ankle pulse wave velocity in patients with systemic lupus erythematosus.

Authors:  Tim K Tso; Hui-Yu Huang; Chen-Kang Chang; Wen-Nan Huang
Journal:  Clin Rheumatol       Date:  2006-01-21       Impact factor: 2.980

10.  Clinical evaluation of insulin resistance and beta-cell function by the homeostasis model assessment in patients with systemic lupus erythematosus.

Authors:  Tim K Tso; Hui-Yu Huang; Chen-Kang Chang; Ying-Ju Liao; Wen-Nan Huang
Journal:  Clin Rheumatol       Date:  2004-05-18       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.